This project has been flagged by a community member as inappropriate due to reason below.*
Expert Interview
Slingshot members are talking to an expert! The topic is:
A Second View: Investigating GSK's recently approved RSV vaccine AREXVY.
Ticker(s): GSKWho's the expert?
Institution: Alliance Immediate and Primary Care
- Physicians assistant who specializes in family and geriatric medicine
- Sees 20-25 patients a month with RSV
Interview Goalto discuss the current treatment landscape for RSV infection and the use of GSK's recently approved RSV vaccine AREXVY in patients aged 50 to 59 years old.
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
